Juvenile Idiopathic Arthritis

Exposure to TNF inhibitors nearly triples the risk for psoriasis among children with juvenile idiopathic arthritis, according to data published in the Annals of the Rheumatic Diseases.

Overall satisfaction with telehealth visits was high for pediatric rheumatology patients and their caregivers during the COVID-19 pandemic, though there may be areas for improvement, according to data published in Pediatric Rheumatology.

In this video from ACR Convergence 2021, Kathryn Dao, MD, discusses a presentation based on a podcast, “Take a Pain Check,” for teenagers with rheumatic disease.

Secukinumab is efficacious in children and adolescents with psoriatic arthritis and enthesitis-related arthritis, resulting in a significantly longer time to flare versus placebo, according to data presented at ACR Convergence 2021.

Initial biologic therapy is now the most common treatment for children with systemic juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry, according to data presented at ACR Convergence 2021.

Eye exam reminders at every visit are associated with higher uveitis knowledge among patients with juvenile idiopathic arthritis and their parents, according to data published in Pediatric Rheumatology.

The total annual costs for the family of a patient with juvenile idiopathic arthritis are substantial, ranging from $1,122 to $44,832, with the highest dollar amounts spent on medication and medical appointments, according to data.

Exposure to antibiotics in early life is associated with the later onset of juvenile idiopathic arthritis, according to data published in Pediatric Rheumatology.

Enthesitis-related arthritis and a family history of autoimmune disease are key risk factors for inflammatory bowel disease in juvenile idiopathic arthritis, according to data published in Rheumatology.

Biologic disease-modifying antirheumatic drugs used to treat juvenile rheumatic diseases are excluded entirely from national essential medicines lists in close to two-thirds of all countries in the world, according to data published in Pediatric Rheumatology.